Systemic metabolism in frontotemporal dementia

Objective: To document the metabolic changes in frontotemporal dementia, including serum cholesterol and insulin levels, and compare and contrast these changes to motor neuron disease, where metabolism is proposed to affect disease progression. Methods: A cohort of 90 patients with dementia (31 behavioral-variant frontotemporal dementia [bvFTD], 30 semantic dementia [SD], and 29 Alzheimer disease [AD]) underwent fasting blood cholesterol, glucose, and peripheral insulin level analysis. Insulin resistance was calculated using the homeostasis model assessment of insulin resistance (HOMA-IR). These results were compared with a cohort of 19 control subjects. Results: The bvFTD cohort had lower high-density lipoprotein (HDL) cholesterol levels compared with control and AD groups, and increased total cholesterol/HDL ratio and triglyceride levels compared with the control group. The SD cohort had increased triglyceride levels compared with control subjects. Both FTD groups had increased fasting insulin levels and HOMA-IR index compared with the control group, and this remained increased in the subjects with bvFTD compared to subjects with AD. Conclusion: Both patients with bvFTD and those with SD have increased triglyceride and insulin levels and lower HDL cholesterol levels compared with controls, suggesting a state of peripheral insulin resistance. These factors have been found to affect prognosis in motor neuron disease favorably, although insulin resistance has been proposed as a mechanism promoting neurodegeneration. We discuss the potential role of metabolism in FTD pathophysiology and progression.

[1]  J. Hodges,et al.  Quantifying the eating abnormalities in frontotemporal dementia. , 2014, JAMA neurology.

[2]  C. Gutiérrez‐Repiso,et al.  Modifications of the homeostasis model assessment of insulin resistance index with age , 2014, Acta Diabetologica.

[3]  S. Paganoni,et al.  Trials of Antidiabetic Drugs in Amyotrophic Lateral Sclerosis: Proceed with Caution? , 2013, Neurodegenerative Diseases.

[4]  D. Levy,et al.  Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients , 2013, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[5]  M. Swash,et al.  Controversies and priorities in amyotrophic lateral sclerosis , 2013, The Lancet Neurology.

[6]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[7]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[8]  O. Hardiman,et al.  Amyotrophic lateral sclerosis , 2011, The Lancet.

[9]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[10]  A. Ludolph,et al.  Energy metabolism in amyotrophic lateral sclerosis , 2011, The Lancet Neurology.

[11]  J. Kassubek,et al.  Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis , 2011, Journal of Neurology.

[12]  M. York,et al.  A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[13]  Daniele Sancarlo,et al.  Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease , 2010, Ageing Research Reviews.

[14]  M. Hornberger,et al.  Clinical Staging and Disease Progression in Frontotemporal Dementia Supplemental Data at Www.neurology.org , 2022 .

[15]  M. York,et al.  ALS disease onset may occur later in patients with pre‐morbid diabetes mellitus , 2010, European journal of neurology.

[16]  Lucette Lacomblez,et al.  Impaired glucose tolerance in patients with amyotrophic lateral sclerosis , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[17]  Daniele Sancarlo,et al.  Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. , 2010, Journal of Alzheimer's disease : JAD.

[18]  A. Chiò,et al.  Lower serum lipid levels are related to respiratory impairment in patients with ALS , 2009, Neurology.

[19]  L. Mascitelli,et al.  USE OF STATINS AND INCIDENCE OF DEMENTIA AND COGNITIVE IMPAIRMENT WITHOUT DEMENTIA IN A COHORT STUDY , 2009, Neurology.

[20]  J. Desport,et al.  High metabolic level in patients with familial amyotrophic lateral sclerosis , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[21]  L. Mascitelli,et al.  DYSLIPIDEMIA IS A PROTECTIVE FACTOR IN AMYOTROPHIC LATERAL SCLEROSIS , 2008, Neurology.

[22]  V. Kostic,et al.  Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. , 2008, Archives of neurology.

[23]  A. Kiss,et al.  Are statin medications safe in patients with ALS? , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[24]  Jennifer L. Whitwell,et al.  VBM signatures of abnormal eating behaviours in frontotemporal lobar degeneration , 2007, NeuroImage.

[25]  M. Kiernan,et al.  Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[26]  John R Hodges,et al.  The Addenbrooke's Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screening , 2006, International journal of geriatric psychiatry.

[27]  Å. Petersén,et al.  Hypothalamic–endocrine aspects in Huntington's disease , 2006, The European journal of neuroscience.

[28]  C. Clark,et al.  Frontotemporal lobar degeneration with motor neuron disease: a clinical and pathological spectrum. , 2006, Archives of neurology.

[29]  P. Preux,et al.  Hypermetabolism in ALS: Correlations with Clinical and Paraclinical Parameters , 2006, Neurodegenerative Diseases.

[30]  J. Levy,et al.  Use and abuse of HOMA modeling. , 2004, Diabetes care.

[31]  D. Bennett,et al.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. , 2004, Archives of neurology.

[32]  Suzanne Craft,et al.  Insulin and neurodegenerative disease: shared and specific mechanisms , 2004, The Lancet Neurology.

[33]  J R Hodges,et al.  Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer’s disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[34]  G. Dagenais,et al.  Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. , 2001, Archives of internal medicine.

[35]  B Miller,et al.  Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. , 2001, Archives of neurology.

[36]  B. Beaufrère,et al.  Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. , 2001, The American journal of clinical nutrition.

[37]  Sasha Bozeat,et al.  Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? , 2000, Journal of neurology, neurosurgery, and psychiatry.

[38]  A Hofman,et al.  Diabetes mellitus and the risk of dementia , 1999, Neurology.

[39]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[40]  R. Penn,et al.  Stiff‐man syndrome treated with intrathecal baclofen , 1993, Neurology.

[41]  R Sandyk,et al.  The relationship between diabetes mellitus and Parkinson's disease. , 1993, The International journal of neuroscience.

[42]  B. Festoff,et al.  Insulin resistance in amyotrophic lateral sclerosis , 1984, Journal of the Neurological Sciences.